UY29400A1 - Base libre de lercanidipina. - Google Patents

Base libre de lercanidipina.

Info

Publication number
UY29400A1
UY29400A1 UY29400A UY29400A UY29400A1 UY 29400 A1 UY29400 A1 UY 29400A1 UY 29400 A UY29400 A UY 29400A UY 29400 A UY29400 A UY 29400A UY 29400 A1 UY29400 A1 UY 29400A1
Authority
UY
Uruguay
Prior art keywords
free base
lercanidipine free
lercanidipine
purity
formulation
Prior art date
Application number
UY29400A
Other languages
English (en)
Inventor
Amadeo Lionadi
Gianni Motta
Fabio Berlati
Ilaria Candiani
Francesco Corlella
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of UY29400A1 publication Critical patent/UY29400A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención proporciona una base libre de lercanidipina sustancialmente pura, que tiene una pureza de por lo menos 95%, preferentemente por lo menos aproximadamente 97%, más preferentemente por lo menos aproximadamente 99%, y aun más preferentemente por lo menos aproximadamente 99,5%. La base libre de lercanidipina de la presente invención es formada como un sólido amorfo que es fácillmente manipulado y particularmente adecuado para la formulacinon de composiciones farmacéuticas.
UY29400A 2005-02-25 2006-02-24 Base libre de lercanidipina. UY29400A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65674105P 2005-02-25 2005-02-25

Publications (1)

Publication Number Publication Date
UY29400A1 true UY29400A1 (es) 2006-06-30

Family

ID=36587241

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29400A UY29400A1 (es) 2005-02-25 2006-02-24 Base libre de lercanidipina.

Country Status (18)

Country Link
US (1) US20060199849A1 (es)
EP (1) EP1853562A1 (es)
JP (1) JP2008531516A (es)
KR (1) KR20070105978A (es)
CN (1) CN101142186A (es)
AR (1) AR053023A1 (es)
AU (1) AU2006218027A1 (es)
BR (1) BRPI0608136A2 (es)
CA (1) CA2597992A1 (es)
EA (1) EA200701686A1 (es)
IL (1) IL184348A0 (es)
MX (1) MX2007010362A (es)
NO (1) NO20074873L (es)
PE (1) PE20061393A1 (es)
TW (1) TW200640860A (es)
UY (1) UY29400A1 (es)
WO (1) WO2006089788A1 (es)
ZA (1) ZA200708126B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100651212B1 (ko) * 2004-10-27 2006-12-01 제일약품주식회사 무정형 레르카니디핀의 제조방법
WO2008040367A1 (en) * 2006-08-01 2008-04-10 Union Quimico-Farmaceutica S.A. Lercanidipine hydrobromide, a process for its preparation, crystalline forms and compositions thereof
DE102010005124A1 (de) * 2010-01-19 2012-03-01 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung umfassend Lercanidipin
CN102558032B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 一种无定形盐酸乐卡地平及其制备方法
CN102531999B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 无定形盐酸乐卡地平及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US5696139A (en) * 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
US5912351A (en) * 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
IT1298732B1 (it) * 1998-03-13 2000-02-02 Recordati Chem Pharm Composizioni farmaceutiche orali assumibili senza liquidi,contenenti complessi di inclusione
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US20030069285A1 (en) * 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
US20030180355A1 (en) * 2001-10-16 2003-09-25 Amedeo Leonardi Combination therapy for hypertension
US20040147566A1 (en) * 2002-10-16 2004-07-29 Amedeo Leonardi Lisinopril/lercanidipine combination therapy
JP2006504800A (ja) * 2002-10-16 2006-02-09 レコーダチ アイルランド リミテッド リシノプリル/レルカニジピンの組み合わせ治療
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
BRPI0417043A (pt) * 2003-12-01 2007-02-06 Lifecycle Pharma As composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição
TW200613275A (en) * 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules

Also Published As

Publication number Publication date
CN101142186A (zh) 2008-03-12
KR20070105978A (ko) 2007-10-31
CA2597992A1 (en) 2006-08-31
JP2008531516A (ja) 2008-08-14
PE20061393A1 (es) 2007-01-16
WO2006089788A1 (en) 2006-08-31
EA200701686A1 (ru) 2008-02-28
TW200640860A (en) 2006-12-01
BRPI0608136A2 (pt) 2009-11-17
EP1853562A1 (en) 2007-11-14
ZA200708126B (en) 2008-11-26
AR053023A1 (es) 2007-04-18
AU2006218027A1 (en) 2006-08-31
IL184348A0 (en) 2007-10-31
NO20074873L (no) 2007-11-22
MX2007010362A (es) 2007-10-17
US20060199849A1 (en) 2006-09-07

Similar Documents

Publication Publication Date Title
CY1122861T1 (el) Φαρμακευτικες συνθεσεις της αμορφης μορφης ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου
UY29401A1 (es) Clorhidato de lercanidipina amorfo.
CL2017001847A1 (es) Una formulación sólida de dosificación farmacéutica
BRPI0509184A (pt) composições farmacêuticas
ATE528989T1 (de) Kristalline feste rasagilin-base
BRPI0519496A2 (pt) processo para preparar um composto ou uma composiÇço, e, composiÇço
CR10528A (es) Proceso para producir poxvirus y composiciones de poxvirus
ECSP066376A (es) FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
AR058753A1 (es) Uso de composiciones nutricionales con fosfolipidos esfingolipidos y colesterol
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
AR052925A1 (es) Forma cristalina betad del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen
CR11316A (es) Derivado de uracilo o timina para el tratamiiento de la hepatitis c.
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
EA200701462A1 (ru) Распадающаяся при пероральном приёме композиция оланзапина или донепезила
PA8846901A1 (es) Inhibidores de cinasa akt y p70 s6.
UY30778A1 (es) Compuestos de 5,6-dihidro-1h-piridin-2-ona
ECSP088635A (es) Formulaciones orales que comprenden tigeciclina
BRPI0713031B8 (pt) composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos
UY29400A1 (es) Base libre de lercanidipina.
UY31103A1 (es) Composiciones farmaceuticas en base a microparticulas comprendiendo un analogo de somatostatina, proceso de preparacion y aplicaciones
BRPI0408895A (pt) formulações de cladribina para administração oral e transmucosal aperfeiçoada
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
CL2006003449A1 (es) Compuestos derivados de n-(fluoro-pirazinil)-fenilsulfonamidas; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del asma.
UY30023A1 (es) Nueva asociacion de un inhibidor de la corriente sinusal i, y de un inhibidor calcico y las composiciones farmaceuticas que la contienen
BRPI0408848A (pt) formulações orais de cladribine